Medprin Regenerative Medical Technologies Co (SZSE:301033) Research & Development: ¥37.8 Mil (TTM As of Jun. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Medprin Regenerative Medical Technologies Co Ltd SZSE:301033

78 GF Score

Price ¥52.96

GF Value ¥73.38

Valuation Modestly Undervalued

1 Warning Sign

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

What is Medprin Regenerative Medical Technologies Co Research & Development?

Medprin Regenerative Medical Technologies Co SZSE:301033 +3.32% 78 Research & Development is ¥37.8 Mil as of Jun. 2026. GuruFocus rates SZSE:301033 with a GF Score™ of 78/100 and a GF Value™ of ¥73.38 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Medprin Regenerative Medical Technologies Co's Research & Development for the three months ended in Jun. 2026 was ¥8.9 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was ¥37.8 Mil.

Try GuruFocus Premium free for 7 days

Unlock GF Score, GF Value, 30-Y financials, and pro screeners.

Get Started →

Medprin Regenerative Medical Technologies Co (SZSE:301033) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medprin Regenerative Medical Technologies Co Research & Development Related Terms

Medprin Regenerative Medical Technologies Co Research & Development Historical Data

* Premium members only.

The historical data trend for Medprin Regenerative Medical Technologies Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medprin Regenerative Medical Technologies Co Research & Development Chart

Medprin Regenerative Medical Technologies Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Research & Development

Get a 7-Day Free Trial

24.08

27.97

24.32

25.06

34.81

Medprin Regenerative Medical Technologies Co Quarterly Data
	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26	Jun26
Research & Development	Get a 7-Day Free Trial															8.96	7.87	10.69	8.24	8.87

78GF Score

Medprin Regenerative Medical Technologies Co Ltd SZSE:301033

Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

Medprin Regenerative Medical Technologies Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥37.8 Mil.

Frequently Asked Questions Learn more about Research & Development →

What does a Research & Development of ¥37.8 Mil mean?

Medprin Regenerative Medical Technologies Co (SZSE:301033) has a Research & Development of ¥37.8 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Medprin Regenerative Medical Technologies Co and its competitors.

Is Medprin Regenerative Medical Technologies Co's Research & Development too high?

Medprin Regenerative Medical Technologies Co's current Research & Development is ¥37.8 Mil. Overall, Medprin Regenerative Medical Technologies Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Medprin Regenerative Medical Technologies Co's Research & Development compare to ABT and SYK?

Medprin Regenerative Medical Technologies Co's Research & Development of ¥37.8 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Research & Development for a Medical Devices & Instruments company?

A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Research & Development mean?

A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Medprin Regenerative Medical Technologies Co and its competitors. Medprin Regenerative Medical Technologies Co's current Research & Development is ¥37.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Medprin Regenerative Medical Technologies Co stock overvalued right now?

Based on GuruFocus' analysis, Medprin Regenerative Medical Technologies Co (SZSE:301033) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥73.38, compared to a current price of ¥52.96 — trading 27.8% below its estimated fair value. The current Research & Development is ¥37.8 Mil. Medprin Regenerative Medical Technologies Co's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Research & Development calculated?

Research & Development is calculated from a company's financial statements. For Medprin Regenerative Medical Technologies Co (SZSE:301033), the current Research & Development is ¥37.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medprin Regenerative Medical Technologies Co (SZSE:301033) Overvalued in 2026?

Based on GuruFocus' analysis, Medprin Regenerative Medical Technologies Co stock appears to be undervalued. The current stock price of ¥52.96 is trading 27.8% below its estimated GF Value™ of ¥73.38. GuruFocus considers Medprin Regenerative Medical Technologies Co to be Modestly Undervalued.

Key valuation signals for SZSE:301033:

Research & Development: ¥37.8 Mil
GF Value™: ¥73.38 vs. price of ¥52.96 (27.8% below fair value)
GF Score™: 78/100 with 1 warning sign

No single metric tells the full story. See the SZSE:301033 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →